Sites Under Pressure: What Clinical Research Sites Need to Operate, Compete, and Deliver

Clinical research sites are navigating a convergence of mounting pressures: financial instability driven by payment delays, misalignment between protocol demands and site capabilities, technology systems that create more burden than they relieve, and intensifying competition for studies.

At the same time, forward-thinking sites are finding new ways to differentiate through artificial intelligence (AI) adoption, strategic feasibility practices, and stronger sponsor partnerships.

The pressures facing sites are not new, but their intensity is increasing as trial complexity grows, site capacity tightens, and competition for experienced investigators accelerates. Understanding what sites need to operate effectively is no longer a courtesy, but rather a prerequisite for successful trial execution.

Here are 10 questions addressing the key challenges and opportunities facing clinical research sites today.

1. Why is site financial stability such a persistent challenge in clinical research?

Approximately 80% of sites operate with six months or less of cash on hand, making timely payment a survival issue rather than a preference. Over 70% of sites report experiencing financial stress, with many taking out loans to sustain operations while awaiting reimbursement. These pressures are compounded by growing trial complexity, particularly in oncology, rare disease, and cell and gene therapy, where coordination demands have increased substantially without corresponding improvements in payment reliability.

2. How is payment experience influencing site decisions about sponsor relationships?

Sites increasingly have options in a competitive trial landscape, and payment experience is shaping which sponsors they choose to work with. Site administrators remember which sponsors create friction and which are responsive and transparent. Practices such as holdbacks, which can reach into six figures, and overly complex payment structures tied to detailed procedural calculations, generate frustration that accumulates over time. Sponsors who do not address these issues risk being deprioritized or excluded from future studies by the most experienced sites.

3. What does transparency in site payments actually require?

Transparency means more than visibility into payment status. Sites need to know what they will be paid, when they will be paid, and how those amounts are calculated relative to specific patients, visits, and procedures. Despite advances in clinical technology, many sites still receive payments with no explanation of what they cover. Establishing clear points of contact for payment questions, communicating proactively about delays, and providing real-time reconciliation data are practical steps that meaningfully reduce friction and build trust.

4. Why does misalignment between site selection and protocol demands remain such a widespread problem?

Feasibility processes were designed to identify capable sites but in practice function as high-volume, time-constrained questionnaires that struggle to capture how sites actually operate. Important factors such as workflow efficiency, staff experience, competing study demands, and patient population dynamics are difficult to convey in standardized formats. The result is that capable sites are sometimes bypassed while studies move forward with sites that are not operationally fit, creating predictable downstream problems in startup, enrollment, and data quality.

5. What separates high-performing sites in how they approach feasibility?

High-performing sites treat feasibility as a strategic function rather than an administrative task. Before responding, they assess current workload, staffing capacity, and competing studies to ensure responses reflect real readiness rather than optimistic estimates. They communicate their patient access, operational strengths, and practical requirements clearly and specifically. Over time, this builds sponsor and CRO confidence, shifting site selection from interpretation to trust. Overcommitting may secure a study in the short term, but consistently creates execution challenges that damage long-term relationships.

6. What are the most significant gaps in current clinical trial technology ecosystems?

The most critical gap is workflow guidance. Sites running multiple trials across different sponsors rely on memory, handbooks, or handwritten notes to navigate study-specific tasks because technology rarely tells users what to do next. Fragmented systems with separate logins, training requirements, and inconsistent interfaces compound cognitive load. A fully digitized workflow management system that guides site staff through trial-specific tasks in real time, reducing reliance on recall and workarounds, remains largely unrealized but represents the most meaningful near-term opportunity in eClinical technology.

7. How does poor technology usability affect site performance and data quality?

When systems are slow, unintuitive, or difficult to navigate, site staff find workarounds or defer tasks, creating inconsistency and increasing the risk of errors. Poor usability also erodes adoption: if a tool requires significant effort to use, busy coordinators managing multiple studies will minimize their engagement with it. The consequences extend to data quality, compliance, and ultimately patient safety. Technology that is purpose-built, easy to navigate, and configured to the specific demands of each trial enables faster, more reliable execution with less cognitive burden on site teams.

8. How should sponsors think about integrating digital and physical supply chain management?

The digital and physical supply chain should be treated as a single continuous system rather than two separate functions. Digital tools for drug ordering, randomization, and inventory management directly trigger the physical activities of picking, packing, and shipping. The value of this integration comes from real-time visibility into site and patient performance, which allows sponsors to adjust assumptions made at study startup as actual enrollment patterns emerge. Sponsors should assess whether they have the internal supply chain expertise to manage this effectively or whether closer partnership with their technology provider is needed.

9. How are leading sites using AI to strengthen their competitive position?

Forward-thinking sites are using AI to scan large patient record sets in minutes, identify eligible candidates against protocol criteria, and submit feasibility responses backed by data-driven enrollment projections rather than rough estimates. One site reported an 80% reduction in feasibility completion time and a 95% patient conversion rate on an obesity trial using AI-powered pre-screening, results that prompted the sponsor to award four additional studies. These capabilities are shifting how sponsors evaluate sites, with data-driven performance becoming a differentiator alongside traditional measures of experience and patient access.

10. How should sites and sponsors be approaching the relationship differently to improve trial outcomes?

Sites are not interchangeable vendors; they are long-term collaborators with institutional knowledge, community relationships, and operational expertise that take years to build. Sponsors who treat sites accordingly, with transparent payment practices, earlier engagement during protocol design, realistic feasibility expectations, and responsive communication, consistently build stronger partnerships and gain preferential access to high-performing sites. For their part, sites that invest in data capabilities, communicate capacity honestly, and approach feasibility strategically are better positioned to secure and execute studies in an increasingly competitive landscape.

The challenges facing clinical research sites reflect deeper structural issues in how the industry designs, funds, and operationalizes trials. Payment inequity, feasibility misalignment, and technology burden are not inevitable. However, they are addressable through deliberate process improvement and a genuine commitment to treating sites as strategic partners. Sponsors who act on that commitment will find themselves with more reliable execution, stronger data, and preferential access to the sites that matter most.

This FAQ article is based on four previous pieces of Applied Clinical Trials content:

Sites Are Walking Away: Why Payment Experience is the New Competitive Advantage

The Feasibility Gap: Why Strong Sites Miss Study Opportunities

Building the Clinical Trial Tech Stack of Tomorrow: Q&A with Cheryl Kole, Almac Clinical Technologies

From the Frontlines of SCOPE 2026: Sites Jump on AI Opportunity